(P101) Does Maximum SUV From F-18 PET Scan Predict Outcomes for Early-Stage Non–Small-Cell Lung Cancer Treated With Stereotactic Body Radiotherapy (SBRT)?

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

We did not find an association of SUVmax with recurrences or death; however, the sample size was relatively small, and the power to detect differences was low. These findings will be further evaluated in a larger multicenter study in the future.

Corey J. Hobbs, MD, Stephen J. Ko, MD, Nitesh N. Paryani, MD, Michael G. Heckman, MS, Nancy N. Diehl, BS, Jennifer L. Peterson, MD, Katherine S. Tzou, MD, Robert C. Miller, MD, Laura A. Vallow, MD, Steven J. Buskirk, MD; Mayo Clinic Florida

PURPOSE: Prior studies have shown mixed results regarding the predictive value of positron emission tomography (PET) scan following definitive treatment of early-stage lung cancers. The primary outcome of this study was to evaluate the association of maximum standard uptake value (SUVmax) on PET scan with recurrence and survival in patients with lung cancer who were treated with stereotactic body radiotherapy (SBRT). Secondary outcomes were to evaluate associations of baseline patient characteristics with SUVmax, recurrence, and survival.

MATERIALS AND METHODS: A total of 61 lung cancer patients with a documented pretreatment SUVmax and treated with SBRT between 2008 and 2014 were included in this study. Baseline information was collected regarding age, gender, lesion size, SUVmax, glucose at time of PET, T stage, histology, nodal evaluation, and total radiation dose. Examined recurrences included local, nodal, ipsilateral lung, contralateral lung, and distant metastases. Time to death and cause of death were also recorded. Median clinical follow-up was 12.7 months (range: 2.8–52.9 mo). The median SUVmax of the cohort was 6.4. A total of 54 patients (89%) had biopsy-proven malignancy.

RESULTS: Baseline characteristics between patients with a low (< 6.4) and high (≥ 6.4) SUVmax were similar, except for lesion size in the high-SUVmax group (median: 2.2 cm vs 1.7 cm; P < .001) and higher T stage (1b or 2a: 71.0% vs 36.7%; P = .018). Adenocarcinomas were more common in the low-SUVmax group (76.0% vs 41.1%), while squamous cell carcinomas were less common (8.0% vs 44.8%).

A total of 16 patients (26.2%) experienced any recurrence; 9 patients (14.8%) experienced nodal recurrence, 3 patients (4.9%) experienced same lung recurrence, and 5 patients (8.2%) experienced distant recurrence. Also, 18 patients (29.5%) died during follow-up.

There was no evidence of a difference in recurrence outcomes between the two groups. An evaluation of associations of baseline patient characteristics with the three most common outcomes of nodal or same lung recurrence, any recurrence, and death was performed. The only baseline variable that was significantly associated with any of these outcomes was serum glucose at time of PET; patients with a glucose value higher than the median of 103 mg/dL had an increased risk of nodal or same lung recurrence (relative risk [RR] = 6.77; P = .017) and any recurrence (RR = 3.76; P = .027).

CONCLUSION: We did not find an association of SUVmax with recurrences or death; however, the sample size was relatively small, and the power to detect differences was low. These findings will be further evaluated in a larger multicenter study in the future.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Patients with locally advanced or metastatic urothelial cancer and visceral disease may particularly benefit from enfortumab vedotin plus pembrolizumab, according to Amanda Nizam, MD.
High-grade adverse effects with zanidatamab plus palbociclib and fulvestrant seem to be uncommon in patients with HER2-positive, hormone receptor–positive, metastatic breast cancer, according to Sara Hurvitz, MD, FACP.
Black male patients with breast cancer appear to experience worse survival outcomes compared with White patients when controlling for clinicopathological variables, according to Jason (Jincong) Q. Freeman, MPH, MS.
Results from the ECOG-ACRIN E4112 trial appear to support the use of DCIS scores for identifying patients with breast cancer who may be eligible to omit radiotherapy following MRI-guided surgery.
Providers should inform patients with breast cancer that selecting later-line therapies following prior treatment with CDK4/6 inhibitors is a “developing area,” says Abigail M. Johnston, JD.
Data from the phase 3 NATALEE trial highlight a positive toxicity profile for ribociclib as an adjuvant therapy for patients with hormone receptor–positive, HER2-negative breast cancer, says Neil M. Iyengar, MD.
Future research will focus on ctDNA dynamics change over time in the full translational cohort of patients with hormone receptor–positive breast cancer in the phase 3 monarchE study, says Stephanie L. Graff, MD.
Findings from a National Cancer Database analysis highlight no statistically significant differences in survival outcomes with chemotherapy for patients over 81 years old with triple-negative breast cancer compared with those who do not receive chemotherapy.
Related Content